Neumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back Unlikely
Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...
Neumora Therapeutics’ navacaprant did not meet primary endpoint in depression
Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate Phase ...
BioPharma Dive5d
Neumora plummets on depression drug data
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an ...
Monthly Prescribing Reference5d
Navacaprant Falls Short in Major Depressive Disorder Trial
Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.
BioSpace5d
Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
Contract Pharma4d
Neumora’s KOSTAL-1 Study of Navacaprant Yields Disappointing Results
The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...
Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials
Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and ...
Neumora Shares Plunge As Navacaprant Misses Key Endpoints In Major Depressive Disorder Trial
Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...
Neumora drops as depression therapy fails in late-stage trial
Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...